Study finds link between diet diversity and reduced depression risk in knowledge workers

In­ter­cept Phar­ma­ceu­ti­cals’ NASH drug obeti­cholic acid was re­ject­ed by the FDA for a sec­ond time on Thurs­day, and the com­pa­ny says it will now dis­con­tin­ue

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  Im­prove­ments need­ed to patch the cy­ber­se­cu­ri­ty vul­ner­a­bil­i­ties